ANRO Alto Neuroscience, Inc.
Pharmaceutical Preparations · NYSE · SEC CIK 1999480 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-52.9%
TTM EPS YoY-0.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-46.6%
ROA-40.2%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets9.2%
Debt / equity0.05x
Current ratio18.12x
Interest coverage-48.48x
Cash quality & payout
Operating cash flow / net income0.83x
Accruals ratio-6.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 |
|---|---|---|---|
| Income statement | |||
| Revenue | — | — | — |
| R&D expense | $45.62M | $47.00M | $30.29M |
| SG&A expense | $20.75M | $21.61M | $7.52M |
| Operating income | -$66.36M | -$68.61M | -$37.81M |
| Interest expense | $2.47M | $1.38M | $1.37M |
| Income tax | $0 | $0 | $0 |
| Net income | -$63.24M | -$61.43M | -$36.30M |
| EBITDA | -$65.70M | -$68.11M | -$37.44M |
| EPS (basic) | -2.19 | -2.50 | -9.73 |
| EPS (diluted) | -2.19 | -2.50 | -9.73 |
| Weighted avg. shares (diluted) | 28.85M | 24.60M | 3.73M |
| Balance sheet | |||
| Cash & equivalents | $176.48M | $168.73M | $82.55M |
| Current assets | $177.72M | $169.34M | $85.39M |
| PP&E, net | $1.87M | $2.67M | $1.11M |
| Total assets | $184.69M | $177.54M | $86.63M |
| Current liabilities | $11.32M | $10.01M | $5.61M |
| Short-term debt | $585,000 | $0 | $0 |
| Long-term debt | $16.17M | $10.25M | $9.86M |
| Total debt | $16.76M | $10.25M | $9.86M |
| Total liabilities | $33.55M | $26.08M | $16.82M |
| Shareholders' equity | $151.14M | $151.46M | -$71.67M |
| Net debt | -$159.73M | -$158.47M | -$72.69M |
| Shares outstanding | 31.92M | 26.99M | 3.83M |
| Cash flow statement | |||
| Operating cash flow | -$51.77M | -$47.42M | -$33.45M |
| Capital expenditure | $24,000 | $2.08M | $470,000 |
| Free cash flow | -$51.79M | -$49.50M | -$33.92M |
| Investing cash flow | -$24,000 | -$2.08M | -$470,000 |
| Financing cash flow | $60.08M | $135.69M | $68.13M |
| Depreciation & amortization | $661,000 | $502,000 | $373,000 |
| Stock-based compensation | $8.11M | $7.63M | $2.89M |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.